Psoriasis Clinical Trial

Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis

Summary

Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents.

View Full Description

Full Description

Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents, as determined by the change in the target plaque severity (TPS) rating between Weeks 0 and 4.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Moderate to severe plaque psoriasis between 3% and 20% of Body Surface Area (BSA) with a target plaque severity (TPS) of moderate to severe
At least 1 target site (not on the palms or soles of the feet) with a TPS rating of moderate to severe and with 1 or more elevated, easily palpable, plaques having well-circumscribed margins, and at least 1 cm in diameter
History of stable plaque psoriasis of greater than or equal to 3 months

Exclusion Criteria:

Diagnosis of guttate, generalized pustular, erythrodermic, psoriatic arthritis, or nail psoriasis as the sole or predominant form of psoriasis
Psoriatic arthritis that was not stable or might have required a change in medication during the 4-week study period
Plaque psoriasis requiring treatment on the face, scalp, neck, groin, and armpits

Study is for people with:

Psoriasis

Estimated Enrollment:

2488

Study ID:

NCT00437216

Recruitment Status:

Completed

Sponsor:

Galderma R&D

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

DHC Dimensional HealthCare, Inc. (Clinical Research Organization)
Cedar Knolls New Jersey, 76117, United States

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Estimated Enrollment:

2488

Study ID:

NCT00437216

Recruitment Status:

Completed

Sponsor:


Galderma R&D

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider